Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Cut to Hold at Zacks Research

Zacks Research cut shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports.

A number of other research analysts have also commented on the stock. DZ Bank lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Finally, Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Trading Up 1.0%

Shares of BAYRY stock opened at $12.48 on Monday. The firm has a market capitalization of $49.05 billion, a P/E ratio of -138.65, a price-to-earnings-growth ratio of 4.89 and a beta of 0.68. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $14.85. The firm’s fifty day simple moving average is $12.30 and its 200 day simple moving average is $9.73. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.